OBJECTIVES:in To investigate the impact of apolipoprotein E (apoE) genotype on the response of the plasma lipoprotein profile to eicosapentaenoic acid in (EPA) versus docosahexaenoic acid (DHA) intervention in humans. METHODS AND RESULTS: 38 healthy normolipidaemic males, prospectively recruited on the basis control of apoE genotype (n=20 E3/E3 and n=18 E3/E4), completed a double-blind placebo-controlled cross-over trial, consisting of 3x4 week intervention arms dose of either control oil, EPA-rich oil (ERO, 3.3g EPA/day) or DHA-rich oil (DRO, 3.7g DHA/day) in random order, separated by apoE 10 week wash-out periods. A significant genotype-independent 28% and 19% reduction in plasma triglycerides in response to ERO and DRO carriers was observed. For total cholesterol (TC), no significant treatment effects were evident; however a significant genotype by treatment interaction emerged a (P= .045), with a differential response to ERO and DRO in E4 carriers. Although the genotypextreatment interaction for LDL-cholesterol (P= .089) did studies not reach significance, within DRO treatment analysis indicated a 10% increase in LDL (P= .029) in E4 carriers with a non-significant was 4% reduction in E3/E3 individuals. A genotype-independent increase in LDL mass was observed following DRO intervention (P= .018). Competitive uptake studies studies in HepG2 cells using plasma very low density lipoproteins (VLDL) from the human trial, indicated that following DRO treatment, VLDL(2)were fractions obtained from E3/E4 individuals resulted in a significant 32%(P= .002) reduction in LDL uptake relative to the control. CONCLUSIONS:genotype-independent High dose DHA supplementation is associated with increases in total cholesterol in E4 carriers, which appears to be due to individuals an increase in LDL-C and may in part negate the cardioprotective action of DHA in this population subgroup.

BACKGROUND:programme Heartwatch, a secondary prevention programme in primary care was initiated in 2003, based on the second European Joint Task Force in recommendations for secondary prevention of coronary heart disease (CHD). The aim was to examine the effect of the first 2 with years of the Heartwatch programme on cardiovascular risk factors and treatments. DESIGN: Prospective cohort study of patients with established CHD factors enrolled into the Heartwatch programme. METHODS: Four hundred and seventy (20%) general practitioners nationwide participated in the programme, recruiting 11,542 first patients with established CHD (earlier myocardial infarction, coronary intervention or coronary artery bypass surgery). Clinical data were electronically transferred by pressure, each general practitioner to a central database. Comparison of changes in risk factors and treatments at 1-year and 2-year follow-up central from baseline were made using paired t-test for continuous and McNemar's test for categorical data. RESULTS: Statistically significant changes in were systolic blood pressure, diastolic blood pressure, total and low-density lipoprotien cholesterol and smoking status at 1 and 2 years (P surgery). < .0001) were observed. Little or no improvements were shown for exercise, BMI or waist circumference. Increases in the prescribing of were statins, angiotensin-converting enzyme inhibitors and beta-blockers over the course of the study were observed. CONCLUSION: The Heartwatch programme has demonstrated practitioner significant improvements in the main risk factors and treatments for CHD. More effective interventions are required to reduce BMI, waist 1 circumference and physical inactivity in this population. The increases in treatment uptake are approaching the optimal levels in this population.of

Under that the Road Traffic Act, 2006 handheld mobile phone use whilst driving is an offence liable to a fine and penalty handheld points. The aim of this study was to determine whether there has been a change in driver behaviour following the offence introduction of this legislation. This study found that 2.3% of drivers were still using a handheld mobile phone.